15 results
8-K
EX-99.1
VIR
Vir Biotechnology Inc
3 Aug 23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:14pm
Gates Foundation, and will be conducted by the HIV Vaccine Trials Network. NIAID has provided funding throughout the product development lifecycle of VIR
8-K
EX-99.1
VIR
Vir Biotechnology Inc
4 May 23
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:16pm
of the National Institutes of Health, through grant funding to HVTN. NIAID has provided funding throughout the product development lifecycle of VIR-1388
8-K
EX-99.1
izxhun9pls
19 Jun 20
Patent License Agreement
5:26pm
10-K
2k68 2i9w2shh3oa
26 Mar 20
Annual report
4:08pm
424B4
haluy uphykzfrkrn94c
11 Oct 19
Prospectus supplement with pricing info
5:31pm
S-1/A
o7rbeb8d
30 Sep 19
IPO registration (amended)
6:12am
S-1
EX-10.44
fzxkani9j7en2h2
3 Sep 19
IPO registration
4:40pm
S-1
jc2wtqe5xv6gwd0sb0
3 Sep 19
IPO registration
4:40pm
DRS/A
o61zk0b bd7r
7 Aug 19
Draft registration statement (amended)
12:00am
DRS
x37yzo81s4av
27 Jun 19
Draft registration statement
12:00am
- Prev
- 1
- Next